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Summary 
Tumor necrosis factor (TNF) is a proinflammatory polypeptide that is able to induce a great 
diversity of cellular responses via modulating the expression of a number of different genes. One 
major pathway by which TNF receptors communicate signals from the membrane to the cell 
nucleus involves protein kinase C (PKC).  In the present study, we have addressed the molecular 
mechanism of TNF-induced PKC activation. To this, membrane lipids of the human histiocytic 
cell line U937 were labeled by incubation with various radioactive precursors,  and TNF-induced 
changes in phospholipid, neutral lipid, and water-soluble metabolites were analyzed by thin layer 
chromatography. TNF treatment of U937 cells resulted in a rapid and transient increase of 
l'2'diacylglycerol (DAG), a well-known activator of PKC. The increase in DAG was detectable 
as early as 15 s after TNF treatment and peaked at 60 s. DAG increments were most pronounced 
(~360% of basal levels) when cells were preincubated with [14C]lysophosphatidylcholine, which 
was predominantly incorporated into the phosphatidylcholine (PC) pool of the plasmamembranes. 
Further extensive examination of changes in metabolically labeled phospholipids indicated that 
TNF-stimulated hydrolysis of PC is accompanied by the generation of phosphorylcholine and 
DAG. These results suggest the operation of a PC-specific phospholipase C. Since no changes 
in phosphatidic acid (PA) and choline were observed and the production of DAG by TNF could 
not be blocked by either propranolol or ethanol, a combined activation of phospholipase D and 
PA-phosphohydrolase in DAG production appears unlikely.  TNF-stimulated DAG production 
as well as PKC activation could be blocked by the phospholipase inhibitor/~-bromopbenacylbromide 
(BPB). Since BPB did not inactivate PKC directly, these findings underscore that TNF activates 
PKC  via  formation of DAG.  TNF  stimulation of DAG production could be inhibited by 
preincubation of cells with a monoclonal anti-TNF receptor (p55-60) antibody, indicating that 
activation of a PC-specific phospholipase C  is a TNF receptor-mediated event. 
T 
NF-oL (referred to as TNF) is one of the earliest soluble 
mediators secreted in response to infectious stimuli (1, 
2). TNF can be produced by a variety of tissues, which points 
to important autocrine and paracrine functions. TNF has been 
shown to induce numerous physiologic effects upon diverse 
tissues. Immunostimulatory  capacities of TNF may be bene- 
ticial  to  the host.  However, protracted secretion of large 
amounts of TNF has also been implicated in the pathogen- 
esis of clinical syndromes like septic shock, cachexia, and le- 
thal outcome of cerebral malaria (for review see reference 3). 
In addition, TNF appears to play a pivotal role in the activa- 
tion  of the  HIV-long  terminal  repeat  enhancer,  thereby 
promoting virus replication and dissemination in the host 
(4, 5). TNF-induced cellular responses are brought about by 
TNF's striking ability to stimulate or downmodulate the ex- 
pression of a large number of genes (for review see reference 
6). Despite the plethora of TNF's bioactivities,  the pathways 
by which TNF signals are communicated to the transcrip- 
tional apparatus in the nucleus are poorly understood. Two 
membrane-associated molecules with molecular masses of 
55-60 kD (termed p60) and 75-80 kD (termed pS0), respec- 
tively, have been identified that bind TNF with high affinity 
and may function as specific cell surface TNF receptors (7-12). 
Recently, both TNF receptor chains have been molecularly 
cloned (13-18). Evidence that p60 or p80 TNF receptor chains 
are directly involved in TNF signaling came from studies using 
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bodies that compete for binding apparently do not inhibit 
TNF  action.  In contrast,  most  of the  anti-p60  antibodies 
reported exhibit agonistic activity, that is, are able to elicit 
TNF responses (20). Recently, Thoma et al.  (21) described 
a monoclonal anti-p60 antibody, H398,  that competed for 
TNF binding and inhibited cellular responses to TNF. While 
the functional significance of p80 has yet to become resolved, 
these observations clearly established that the TNF receptor 
chain p60 is crucially involved in triggering certain TNF signal 
transfer reactions. Sequence analysis of both receptor chains 
revealed no homologies to functional domains of tyrosine or 
serine/threonine-specific protein kinases. Thus, TNF receptor 
signaling  across  the membrane  is still unclear. 
One of the membrane-associated events triggered by TNF 
receptors is the activation of phospholipase A2 (PLA2) 1 (22- 
26), which releases arachidonic acid (AA) and lysophosphati- 
dates. AA can be metabolized to leukotrienes and prostagland- 
ins, potent mediators of inflammatory processes. In addition, 
protein kinases (PK) appear to play a crucial role in TNF 
signal transduction pathways (27-31), and a number of cel- 
lular substrates for TNF-responsive PK have been detected 
(32-39). We have recently shown that TNF stimulates trans- 
location and activation of PKC (30). The mechanism of PKC 
activation,  however, remained unclear.  Certain polypeptide 
growth factors activate PKC via stimulating a phospholipase C 
(PLC) that hydrolyzes phosphatidyl-inositol 4,5 biphosphate 
(PIP2)  to diacylglycerol (DAG)  and  inositol  1,4,5-triphos- 
phate (IP3) (see reference 40 for review). Strikingly, TNF ap- 
pears to stimulate PKC in the absence of PIPs turnover. We 
show here that TNF can stimulate a phosphatidylcholine (PC)- 
specific  PLC that  hydrolyzes PC instead to generate phos- 
phorylcholine and DAG, which is probably responsible for 
subsequent activation  of PKC. 
Materials  and Methods 
Cell Culture and Biological Reagents.  U937 cells were obtained 
from the American Type Culture Collection (Rockville, MD) and 
maintained  under  standard conditions  as described (32). Highly 
purified human rTNF-c~ (sp act 5  x  107 U/mg) was provided by 
Dr. G./klolf (Boehringer Research Institute, Vienna, Austria). The 
mAb done H398, directed against the TNF receptor chain (p60), 
has been described recently by Thoma et al. (21). 
Intracelhlar Ca  2+ Measurements.  Loading of U937 cells with 
the fluorescent intracelhlar  Ca  2+  chelator  dye Quin2 was per- 
formed  essentially  as  described  by Charest  et  al.  (41). Ca  2+- 
dependent  Quin2  fluorescence  was  determined  in  a  Farrand 
fluorimeter (model A-3; LKB, Freiburg, Germany) which has been 
modified to allow continuous  stirring of the sample. The excita- 
tion wave length was 334 nm and the emission wave length was 
492 nm. Cytosollc Ca  2+ concentrations were determined accord- 
ing to the method described by Tsien et al.  (42). 
1  Abbreviations used in this paper: AA, arachidonic acid; BPB, p-bromo- 
phenacylbromide; DAG, diacylglycerol; IP3, inositol 1,4,5-triphosphate; 
PA, phosphatidic add; PC, phosphatidylcholine; PEt, phosphatidyl-ethanol; 
PIPe, phosphatidyl-inositol 4,5 biphosphate; PKC, protein kinase C; 
PLA2, phosphotipase  A2; PLC, phospholipase  C; PLD, phospholipase D. 
Pre~ration of ~'C! Choline-la~led Lpo-ehosphatidrlcholine.  107 
U937  ceils were  incubated  with  200  /~Ci [methyl14C]choline 
(Amersham Corp., Arlington Heights, IL) for 48 h. Phospholipids 
were extracted as described by Bllgh and Dyer (43) and separated 
by thin layer chromatography on preparative silica 60 phtes (Merck, 
Darmstadt,  Germany),  using  a CHC13/CH3OH/CH3COOH/ 
H20 (100:60:20:5) solvent system. [14C]PC was identified by au- 
toradiography,  the spots were scraped off, and ["C]PC was ex- 
tracted according to Bligh and Dyer (43). Purified [14C]PC was 
then subjected to 50 U phosphollpase A2 from Naya Naya Venom 
(Sigma Chemical Co., St. Louis, MO) in 100 nM Tris, pH 8.9, 
40 raM CaC12 for 60 h at 37~  followed by CHC13 extraction. 
The CHC13 phase was then loaded onto silica 60 mini-columns, 
and  t-lyso-3-phosphatidyl  [methff4C]choline  was  eluted  with 
CHCI3/CH3OH/H20 (65:35:5). The recovery of t-lyso-3-phos- 
phatidyl-[methyla4C]choline was 70-80%. 
Metabolic Labeling.  For labeling of neutral lipids and phospho- 
lipids, U937 cells were either labeled for 16 h with 14C-oleic acid 
(0.5  #Ci/ml)  (Amersham  Corp.)  (sp act  54.9  mCi/mmol),  or 
[14C]arachidonic acid (0.5 #Ci/ml) (Amersham Corp.) (sp act 54.2 
mCi/mmol), or labeled for 2 h with t-lyso-3-phosphatidylcholine, 
1-[lt4C]palmitoyl at 1 #Ci/ml (sp act 56.8 mCi/mmol) in medium 
containing  5% FCS. For detection of water-soluble choline me- 
tabolites, cells were either labeled for 48 h with [methyl14C]cho  - 
line (1 #Ci/ml, sp act 56.4 mCi/mmol) or for 2 h with t-lyso-3- 
phosphatidyl  [methyl14C]choline  (1  #Ci/ml,  sp  act  22 
mCi/mmol). 
Cell Stimulation and Extraction.  U937 cells were serum-starved 
for 4 h in medium supplemented with 2% BSA. Aliquots of 107 
ceils were suspended in 1 ml PBS and treated for indicated times 
with 100 ng/ml TNF or phorbol ester (PBte, 40 ng/ml;  OAG, 
100/~M; PMA, 100 nM). Incubation  of cells with inhibitors be- 
fore TNF and phorbol ester treatment  was as follows: p-bromo- 
phenacylbromide (BPB), 100/~M, 45 rain; propranolol,  200/~M, 
5 rain; ethanol,  1%, 2 min. Treatments were stopped by immer- 
sion of the sample tubes in methanol/dry ice (-70"C) for 10 s 
followed by a centrifugation  at 4~  in a microfuge. Supernatants 
were collected for  determination  of extracellular, water-soluble 
[methyll~C]choline metabolites, and cell pellets were resuspended 
in cold CH3OH/CHC13/H20 (2.5:1.25:1). Further  extraction  of 
cell pellets and separation into an aqueous phase containing intra- 
cellular [14C]choline metabolites and an organic phase containing 
phospholipids was performed according to the procedure described 
by Bligh and Dyer (43). 
For separation of labeled I'2'DAG and labeled phospholipids, 
cell pellets were resuspended in hexane/isopropanol (3:2), sonicated 
for 2 min, and insoluble material was removed by centrifugation 
for 10 rain at 2,500 g. Supernatants were dried under  nitrogen, 
the material was resuspended in CH3C1/CH3OH/H20 (30:60:8; 
vol/vol/vol),  and desalted by passage through  a Sephadex G-10 
minicolurnn. The eluates were dried under N2. Neutral lipids were 
separated from phospholipids  in  a two-phase  methanol/hexane 
system. 
Thin Layer Chromatography.  Water-soluble compounds  were 
separated on silica gel 60 thin layer phtes using the following system: 
CH3OH/0.5% NaC1/NH~OH  (100:100:2; vol/vol/vol) as  de- 
scribed by Yarvin (44). Phosphorylcholine, glycerophosphorylcho- 
line, acetylcholine, CDP-choline, and choline (Sigma Chemical Co.) 
were used as standards. Samples containing  equal amounts of ra- 
dioactivity were loaded. Plates were exposed to Kodak XAR-films 
and the autoradiographs were analyzed by two-dimensional scan- 
ning using a densitometer (Ultroscan XL; Pharmacia LKB Biotech- 
nology Inc., Freiburg, Germany). To determine the radioactivity 
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off and extracted from the gel. 
Neutral lipids were separated by TLC using in a solvent system 
of  benzene/ethylacetate  (6.5:3.5). Samples  containing  equal amounts 
of radioactivity were loaded. I'2'DAG, l'Ydiacylglyeerol, 1-mono- 
acylglycerol,  triglycerides,  and cholesterol  were applied as standards 
(Sigma Chemical Co.) and visualized by coomassie-staining ac- 
cording to Nakamura and Handa (45). The stained plates as well 
as the autoradiographs were scanned with a two-dimensional laser 
densitometer, the amount of  cholesterol, visualized  by staining, was 
taken as an internal control to correct for equal amount of material 
loaded. 
Phospholipids were separated by TLC using a solvent system 
containing  CHCIffCH3OH/CH3COOH/H20  (100:60:20:5). 
Lyso-phosphatidylcholine,  phosphatidyl-choline, sphingomyeline, 
phosphatidylserine, phosphatidylethanolamine, phosphatidylino- 
sitol, phosphatidylethanol, and phosphatidic acid (Sigma Chem- 
ical Co.) were used as standards and visualized  in iodine vapor. For 
separation of  phosphatidylethanol  from phosphatidic  add and other 
phospholipids, TLC was performed in a solvent system consisting 
of the organic phase of ethylacetate/acetic  add/water (110:20:110). 
Plates were autoradiographed  and analyzed  by two-dimensional  laser 
scanning. Specific  radioactivity  of [methyp4C]choline-labeled  phos- 
pholipids was determined  by scintillation  counting of  corresponding 
spots scraped off the gel. Mass determinations were performed by 
chafing densitometry of TIC plates as described (46). 
PKC Assay.  Activation of PKC by TNF was determined by 
estimation of phorbol ester binding capacity of whole cells as de- 
scribed (30). Briefly, U937 cells (5  x  106 in 1 ml Click's/KPMI 
[Gibco Laboratories, Grand Island, NY)  supplemented with 4 
mg/ml BSA) were left untreated or treated at 37~  with 100 ng/ml 
TNF for various periods of time or with various TNF concentra- 
tions for 3 min. Cells were then washed with 10 ml ice-cold PBS, 
divided in two aliquots, and incubated for 10 min at 37~  in PBS 
containing 4 mg/ml BSA and 40 nM [3H]PBt2 (Amersham Corp.) 
with or without 10 #M of unlabeled competitor PMA (47). Cell- 
associated [3H]PBt2 was separated from free [3H]PBt2 by passage 
through glass fiber filters. Filters were washed five times with PBS 
and radioactivity was determined by liquid scintillation counting. 
Specific binding was estimated by subtracting the mean nonspecific 
binding in the presence of 250-fold excess of unlabeled PMA. 
To determine membrane-associated  PKC activity by the histone 
IIIS phosphorylation assay, 2  ￿  107 cells in 20 ml medium were 
washed at 4~  with homogenization buffer (20 mM Tfis, pH 7.5, 
2 mM EDTA, 50 mM 2-ME, 0.1 mM PMSF, 100 #g/ml leupeptin, 
10 #g/ml aprotinin [Sigma Chemical Co.]), and homogenized in 
0.8 ml of the homogenization buffer by 30 strokes at 1,000 rpm 
in a homogenizer (Potter-Elvehjem, Braun Diessel Biotech, Mel- 
sungen, Germany). Homogenates were first precleared  by centrifu- 
gation (100 g, 5 min) to remove cell debris and nuclei. A second 
centfifugation at 100,000 g for 60 min was performed to separate 
membranes from the cytosol. Membranes were then resuspended 
in homogenization buffer supplemented with 0.1% Triton X-100 
and stirred for 60 min at 5~  to solubilize proteins which were 
recovered by centrifugation at 100,000 g for 60 min. To separate 
PKC from other protein kinases, the Triton X-100 solubilized  mem- 
brane fractions  were subjected  to DE-52 chromatography  according 
to Kikkawa et al. (48). Samples were loaded onto small DEAE- 
cellulose (DE-52; Whatman, Madstone, England) columns that 
had been equilibrated with 20 mM "Iris, pH 7.4, 20 mM EDTA, 
50 mM 2-ME, 4 #g/ml leupeptin,  100 #g/ml aprotinin. After 
loading, columns were washed with the same buffer and PKC ac- 
tivity was eluted with 100 mM NaC1 and stabilized  with 1 mg/ml 
BSA. The PKC activity was assayed  in a final volume of 100 #1 
containing  20  mM Hepes, pH  7.4, 10  mM MgC12, 0.5  mM 
CaCI2, 0.25 mg of histone III-S/ml (Sigma Chemical Co.), 50 #g 
phosphatidyl serine (PS)/ml (Sigma Chemical Co.), 5 #g/ml of 
diolein (Sigma Chemical Co.), and 50 #g of the PKC-containing 
DEAE-cellulose eluate (49). Assays  without both PS and diolein 
served as controls of non-PKC-specific  (phospholipid-independent) 
kinase activity. After thermoequilibration at 30~  for 5 rain, the 
reaction was started by addition of [32P]ATP (Amersham Corp.) 
(50 #M, 40 nCi/nmol). After 10 min, the reaction was stopped 
by addition of 20 #1 buffer containing 50 mM potassium phos- 
phate, pH 7, 10 mM EGTA, 2 mM EDTA, 5 mM unlabeled ATP, 
and 5 mg BSA/ml. Proteins were precipitated  onto glass fiber filters 
with 25% (wt/vol) TCA, washed under vacuum with 15 m125% 
TCA, and 32p incorporation was determined by liquid scintillation 
counting. 
Results 
TNF Does Not Affect Intracellular Ca  2+ Levels.  To obtain 
information as to the mechanism of TNF activation of PKC, 
we first investigated the effects of TNF on free intracellular 
Ca  2+ levels. U937 cells were loaded with the Ca  2+ chelator 
dye Quin2, and Ca2+-dependent  fluorescence was measured. 
As shown in Fig. 1, rapid influx of Ca  2+ was observed after 
treatment with the Ca  2+ ionophore A23187.  Furthermore, 
stimulation of cells with the mitogen Con A resulted in the 
release of Ca  2+ from internal stores. In contrast, even at very 
high concentrations, TNF had no measurable effect on intra- 
cellular Ca  2  + levels. These results indicate that mechanisms 
other  than  IP3  metabolism  may  be  involved  in  TNF- 
mediated PKC activation. In this regard, it is now well rec- 
ognized that the "classical" activator of PKC, I'2'DAG, can 
also be generated in the absence of PiP2 cleavage by PLC- 
mediated hydrolysis of PC to DAG and phosphorylcholine 
(for review see reference 50).  Therefore, we next examined 
in U937 cells whether TNF may trigger the production of 
I'2'DAG by stimulation of a PC-specific  PLC. 
TNF Induces Generation of  DAG.  To assess TNF-induced 
changes of DAG levels, the phospholipid pool of U937 cells 
was labeled with [14C]oleic acid.  After TNF treatment of 
cells for various periods of time, the amount of I'2'DAG pro- 
duced was analyzed by TLC. As shown in Fig.  2 a, TNF 
transiently  stimulates  the  rapid  production  of  I'2'DAG, 
reaching within 60  s a maximum of 135  _+  2.4%  of the 
amount of untreated cells. When U937 cells were labeled 
instead with 14C-arachidonic acid, which is incorporated pre- 
dominantly at the sn-2 position of the phospholipids, max- 
imal stimulation could be increased to 164  _+  8% of basal 
(unstimulated) levels (Fig. 2 a and Table 1). Changes in other 
14C-labeled neutral lipid components (1-monoacylglycerol, 
I'YDAG, and triglycerides) were not significant (Table I). 
Analysis of 14C-fatty acid incorporation in phospholipids re- 
vealed that arachidonic acid was predominantly incorporated 
into PC (43% of total; Table 1). Since PC makes up a large 
proportion of total membrane phospholipids, possible TNF- 
induced changes of PC levels might well be below the level 
of detection. 
The membrane PC pool could be labeled more selectively 
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Figure 1.  TNF does not stimulate in- 
crease of free intracellular Ca  2+ . U937 
cells  were  loaded  with  Quin2,  and 
Ca  2  +-dependent fluorescence was mea- 
sured  as  described  in  Materials  and 
Methods. 40 #M A23187 (.4), 30 #g/ml 
Con A (B), or TNF at 10 ng/ml (C) 
or 100 ng/ml (D) were added to cells 
when U937 cells were incubated with t-lyso-3-phosphatidyl- 
choline, 1-[14C]palmitoyl. This compound easily inserts into 
the cell membrane and is reacylated by acyltransferases within 
the cell membrane and subsequently integrated  into the PC 
pool. As depicted  in Table 1, the fraction  of radioactive PC 
made  up  65%  of 14C-labeled phospholipids,  when  U937 
at 37~  and the changes in fluorescence 
were monitored continuously. 
cells were incubated for 2 h with r-lyso-3-phosphatidylcholine, 
1-[14C]palmitoyl.  TNF  treatment  of prelabeled  U937  cells 
resulted  in  the  production  of  *4C-labeled  I'2'DAG  with 
identical  time kinetics  compared  to labeling regimes  using 
either  [14C]oleic  acid or [14C]arachidonic acid as metabolic 
precursors (Fig.  2 a). Compared  to the latter labels, the use 
Figure 2.  (a) TNF induces  I'2'DAG production in U937 cells. U937 cells were preincubated  for either 16 h with [14C]oleic acid (O),  [14C]arachi- 
donic acid (A), or for 2 h with t-lyso-3-phosphatidylcholine,  1-[114C]palmitoyl (0).  After serum  starvation  for 4 h, cells were incubated  with 100 
mg/ml TNF for indicated  times. For positive control, U937 cells labeled for 2 h with L-lyso-3-phosphatidylcholine,  1-[114C]palmitoyl were incubated 
with 20 ng/ml PBt2 for 10 min (0).  Neutral lipid metabolites  were extracted  and analyzed by TIC as described in Materials and Methods.  The con- 
tent of labeled  I'2'DAG is expressed as percent  of untreated  controls  as estimated  by two-dimensional  scanning  of the autoradiographs  (inset).  The 
arrow indicates the position of I'2'DAG. (b) TNF dose-dependent  production  of I'2'DAG. [t4C]Arachidonic acid-labeled U937 cells were serum-starved 
and incubated with various TNF concentrations  for I min at 37~  I'2'DAG was quantitated  as described in a. Maximal TNF-stimulated DAG produc- 
tion was taken  as  100%.  The results  of three experiments  (_+  SD) are shown. 
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Distribution of  TNF-induced 
Radioactive precursor*  Metabolite*  ~4C incorporatedS  changesll  Significance~ 
[~4C]arachidonic acid  Neutral lipids  (n  =  4):  %  % 
I'2'DAG  4.6  +  0.51  +65  _+  8.2  /,  <  0.01 
TG  79.4  _+  5.80  +  4  NS 
n.i.  16.0  _+  7.2  _+  12.4  NS 
Phospholipids (n  =  4): 
PC  32.5  _+ 3.0  _+  6.4  NS 
PE  23.2  +  3.1  _+  1.7  NS 
PA  38.0  +  0.4  _+  1.5  NS 
SM  2.5  +  0.2  -+ 0,6  NS 
LPC  1.75  _+ 0.25  +  0.3  NS 
t-lyso-3-phosphatidylcholine, 
1-[14C]palmitoyl  Neutral lipids  (n  =  4): 
I'2'DAG  9.5  +  1.5  +357  _+ 44  p  <  0.004 
TG  63.8  _+  13.2  _+  13.17  NS 
n.i.  26.7  _+  12.3  -+  12.3  NS 
Phospholipids (n  =  4): 
PC  65  _+  7.5  -16  +  5.2  p  <  0.01 
LPC  9  +  2.4  _+ 3.4  NS 
SM  16  +  3.5  _+  5.2  NS 
PA  10  _+  1.7  _+  9.4  NS 
* u937 cells were labeled for 16 h with [14C]arachidonic  acid (0.5/~Ci/ml) or for 2 h with z-lyso-3-phosphatidylcholine,  1-1114C]palmitoyl  (1/~Ci/ml). 
* Neutral lipids and phospholipids were separated and analyzed by TLC as described in Materials and Methods. Abbreviations of metabolites exa- 
mined: I'2'DAG, l'2'diacylglycerol;  TG, triglycetides;  n.i., not identified  neutral lipid component;  PC, phosphatidylcboline;  PE, phosphatidylethanolamine; 
PA, phosphatidic acid; SM, sphingomyelin; LPC, lyso-phosphatidylcholine. 
s The initial distribution of 14C in each metabolite was estimated by two-dimensional scanning of the autoradiographs and is expressed in percent 
(_.* SEM) of 14C in total neutral lipids or total phospholipids, respectively. Shown is the distribution before TNF treatment (t  =  0). 
II In each of the four independent experiments, the values at t = 0 were subtracted from the percent of the total 14C label present in each metabolite 
after 60 s of TNF incubation. The means of changes ( _+ SEM) are shown as percent of untreated controls. 
I Statistical significance was determined by student's t test. NS, not significant (p > 0.05). 
of t-lyso-3-phosphatidylcholine,  1-[14C]palmitoyl revealed a 
substantially greater amplitude of DAG liberation, i.e., 360%, 
over control values.  For positive control,  U937  cells were 
treated for 10 min with phorbol dibutyrate (PBt2),  which 
has been shown to indirectly activate, that is via PKC, a PC- 
specific PLC (51,  52).  A  320%  increase in  I'2'DAG could 
be measured (Fig. 2 a), which is similar to that observed with 
TNF. The production of I'2'DAG is a TNF dose-dependent 
event:  as  shown  in  Fig.  2  b,  half-maximal  production  is 
achieved at 0.5-1.0 ng/ml TNF, which is sufficient to induce 
TNF responses such as growth arrest and differentiation (53). 
TNF.induced  PC Hydrolysis as Source fir DAC.  The en- 
hancement  of  I'2'DAG  levels  observed  with  t-lyso-3- 
phosphatidylcholine,  1-[114C] palmitoyl-labeled cells already 
suggested that PC may be a source for I'2'DAG production. 
To obtain further evidence that PC is indeed the substrate 
of a putatively TNF-responsive phospholipase,  we next la- 
beled U937 cells with  [14C]choline,  which allows to mea- 
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sure changes in water-soluble reaction products catalyzed by 
PLC.  When cells were incubated with  [14C]choline for 48 
h,  the distribution  of 14C-labeled phospholipids  PC,  SM, 
and lyso-PC was 74%, 29%, and 5%, respectively (Table 2). 
Analysis  of  the  water-soluble  components  revealed  that 
~79.4%  of [14C] was incorporated into pchol and ~7.6% 
into free choline. Most of the pchol labeled was located in- 
tracellularly (86%),  while a  minor proportion  (14%)  was 
found extracellularly (data  not shown). 
As  shown in Fig.  3  a,  TNF  treatment  of [14C]choline- 
labeled U937 cells led to a rapid increase of the amount of 
intraceUular pchol, reaching after 30--60 s ~141% of unstimu- 
lated values. The extracellular pchol concentration remained 
constant over the time period examined (not shown). Since 
pchol together with DAG represent the PC cleavage prod- 
ucts generated by a PC-specific PLC, these findings strongly 
suggest  that  this phospholipase is activated by TNF/TNF 
receptor  interactions.  Similar  results  were  obtained  when Table  2.  TNF-induced Changes of PC and Phosphorykholine (pchol) in  U937 Cells 
Distribution of  TNF-induced 
Kadioactive precursor*  Metabolite*  14C incorporatedS  changesll  Significancel 
[methyl~4C]choline  Phospholipid (n  =  5):  %  % 
PC  74.2  •  3.8  -15  •  10.6  p  <  0.01 
LPC  7.0  •  2.7  _+  7.7  NS 
SM  33.2  •  7.4  •  4.0  NS 
Water-soluble (n  =  7): 
pchol  79.4  +  13  + 41.2  _+  10  p  <  0.008 
choline  7.6  •  4.5  _+  7.0  NS 
GPC  13.2  +  3.3  •  5.5  NS 
t-lyso-3-phosphatidyl 
[methyl14C]choline  Phospholipids (n  =  4): 
PC  85  _+  7.5  -26.3  +  6.4  p  <  0.01 
LPC  5  _+  1.4  _+  1.3  NS 
SM  10  +  2.3  _+  2,1  NS 
Water-soluble (n  =  4): 
pchol  93.1  _+  11  +55  _+  13  p  <  0.01 
choline  0.9  _+  0.1  +  0.25  NS 
acetylcholine  0.6  _+  0.08  +  0.2  NS 
GPC  5.4  _+  2.8  _+  13.7  NS 
* U937 cells were labeled for 48 h with [methyl 14C]choline  (1 #Ci/ml) or for 2 h with t-lyso-3-phosphatidylcholine [methyl 14C]choline  (1/~Ci/ml). 
* Phospholipids and water-soluble components were separated and analysed by TLC as described in Materials and Methods. Abbreviations of metabolites 
examined: GPC, glycerophosphorylcholine; LPC, lysophosphatidylcholine; PC, phosphatidylcholine; pchol, phosphorylcholine; SM, sphingomyelin. 
S The initial distribution of 14C in each metabolite  was estimated by two-dimensional scanning of the autoradiographs  and is expressed in percent 
(+ SEM) of [14C] in total phospholipids  or total water-soluble  components, respectively. 
II The means of changes (_+ SEM) in each metabolite  after 60 s of TNF treatment were calculated by subtraction  of the values at t  =  0. In each 
of the four to seven independent experiments,  the values at t  =  0 were subtracted from the percent of the total 14(2 label present in each metabolite 
after 60 s of TNF incubation. The means of changes (_+ SEM) are shown as percent of untreated controls. 
Statistical significance was determined  by student's t test.  NS,  not significant (p > 0.05). 
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Figure 3.  TNF induced changes of 
phospholipids and choline metabolites. 
(a) Cells were incubated  with [14C]- 
choline for 48 h, serum-starved for 4 h, 
and treated with 100 ng/ml TNF for 
indicated  times.  Water-soluble  [14C]- 
choline metabolites were analyzed by 
TIC,  and the content of [14C]pchol 
(0) and [14C]choline (A) was deter- 
mined as described in Materials  and 
Methods. Results are expressed as per- 
cent change of untreated controls and 
represent  the  mean  _+  SD  of  four 
experiments.  (b) U937 cells were la- 
beled  with  t-lyso-3-phosphatidyl, 
[methyl14C]choline for  2  h,  serum- 
starved for 4 h, and treated with 100 
ng/ml TNF for indicated times. Phos- 
pholipids were separated and analyzed 
by TIC: (O) LPC; (A) SM; (O) PC. 
Results  are shown as percent  of un- 
treated controls (mean +_  SD of four 
experiments). 
980  Tumor Necrosis Factor Stimulates l'2'Diacylglycerol  Production t-lyso-3-phosphatidyl  [methy114C]choline  was used as a cho- 
line~headgroup-labeled,  more specific  precursor for PC. When 
U937  cells were incubated  for 2  h  with  this  radioactive 
precursor, 85% of labeled phospholipid metabolites were re- 
covered in PC, and ~o93% of labeled, water-soluble compo- 
nents were detected in pchol, 0.9% in choline, in 0.6% in 
acetylcholine (Table 2). TNF treatment enhanced the levels 
of labeled intracellular pchol to 155% compared to untreated 
control values. In contrast, the levels of both labeled choline 
and acetylcholine remained unchanged. Of note, the rather 
selective  labeling of  PC allowed measurement of  TNF-induced 
PC degradation in U937 cells (Fig. 3 b,  Table 2). 
The time course of PC  degradation paralleled  that  of 
I'2'DAG and pchol production. Moreover, estimation of the 
radioactivity extracted from the TLC plates revealed that the 
26%  reduction of labeled  PC  (39,000  _+  4,200  cpm/106 
cells) was approximately equivalent to the amount of labeled 
pchol  generated  (32,000  +  3,400  cpm/106  cells).  These 
findings confirm the notion that the I'2'DAG produced in 
TNF-treated U937 cells is derived from cleavage  of PC, gener- 
ating pchol as a second cleavage product. 
TNF-induced DAG Production Does Not Result from Phos- 
photipase  D (PLD)Activation.  Besides  PC-PLC, another poten- 
tial source of I'2'DAG could be the PLD-mediated hydrol- 
ysis of PC resulting in the liberation  of phosphatidic  acid 
(PA) and choline (54-57).  Subsequent dephosphorylation of 
PA by phosphatidate phosphohydrolase and phosphorylation 
of choline by a choline kinase could also account for the in- 
crease of  DAG and pchol production observed in TNF-treated 
cells. However, after TNF treatment significant changes of 
intra- and extracellular choline levels could not be detected 
(Fig. 3 a and Table 2). Furthermore, PA levels remained rather 
constant as revealed by TLC analysis of U937 ceils labeled 
with either [14C]arachidonic acid (Table 1) or 32p (data not 
shown). In addition, when the cells were labeled for 2 h with 
L-lyso-3-phosphatidylcholine, 1-[14C]palmitoyl, which more 
selectively labeled the PC pool and allowed for optimal de- 
tection of labeled I'2'DAG (see Fig. 2 a), production of la- 
beled PA was not measurable (Table 1 and Fig. 4 a). To evaluate 
in more detail whether a PA phosphohydrolase is involved 
in TNF-stimulated DAG production, the effect  of  propanolol, 
a phosphohydrolase inhibitor (55, 58), on the formation of 
TNF-induced DAG was examined. In the absence of TNF, 
propanolol  increased the basal levels of labeled PA by its ac- 
tion on constitutive PA-phosphohydrolase activity, but treat- 
ment with TNF did not result in a further accumulation of 
PA (Fig. 4 a).  Notably,  in the same experiment, the TNF- 
stimulated production of labeled DAG was not prevented by 
propanolol  (Fig. 4 b). Together,  these results indicate that 
PLD-derived PA is not the primary source of  DAG formation. 
To provide further evidence that PLD is not involved in 
DAG production, we next assessed PLD more directly by 
investigation of possible formation of labeled phosphatidyl- 
ethanol (PEt), which would be expected from PLD's trans- 
phosphatidylation  activity in the presence of  ethanol (57, 59, 
60). In various cell lines, activation of PLD by phorbol esters 
results in formation of PA and of PEt, in the presence of  eth- 
anol (61-63).  As a positive control, U937 cells previously 
981  Sch~itze  et al. 
Figure 4.  TNF-stimulated I'2'DAG production is not derived from PA 
dephosphorylation. Serum-starved U937 cells were labeled with L-lyso-3- 
phosphatidylcholine, 1-[114C]palmitoyl for 2 h.  (a) Cells untreated (O) 
or preincubated with 200 #M propranolol for 5 min (0) were incubated 
with 100 ng/ml TNF for indicated times. Changes in labeled PA were 
estimated by two-dimensional scanning  of autoradiographs of phospho- 
lipids  (inset)  after separation by TLC (see Materials and Methods). Results 
of three independent experiments are expressed as percent of untreated 
controls (+  SEM). (b) Cells were treated with 100 ng/ml TNF for indi- 
cated times (O), or 100 nM PMA ([[]) or 100/~M OAG (A) for 20 min. 
Solid symbols represent  values  revealed in the presence  of propanolol. 
Changes in labeled DAG were estimated after separation of neutral lipids 
as described  in a  (result  from three experiments  +-  SEM). 
labeled with t-3-1yso phosphatidylcholine,  1-[t4C]palmitoyl 
were therefore incubated for 20 min with PMA and OAG 
in the presence of 1% ethanol, resulting in a 85% and 100% 
stimulation of labeled PEt (Fig. 5 a),  indicating  activation 
of  a PLD. In contrast, TNF treatment failed to stimulate PEt 
production, thus indicating that TNF does not activate PLD 
within the time period examined. Moreover, ethanol treat- 
ment did not prevent TNF-stimulated DAG production (Fig. 
5 b). 
Finally, to rule out the possibility  that TNF  stimulates 
a PLD acting on phospholipid pools not readily labeled with 
the isotopic precursors used, we estimated changes in total 
PA mass. Analysis of  separated  phospholipids by charring den- 
sitometry revealed an increase in PA in response to treatment 
with OAG and PMA (Fig. 6).  In contrast, TNF did not 
significantly affect the amount of PA. 
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Figure 5.  (a) TNF does not stimulate the formation of PEt.  Serum- 
starved U937 cells were labeled as described in Fig. 4. Cells were prein- 
cubated with 1% ethanol for 2 min and then stimulated with 100 ng/ml 
TNF (0) for indicated times, or with 100 #M OAG (A) or 100 nM PMA 
(11) for  20 rain. The content of labeled PEt  was estimated  by two- 
dimensional scanning of the autoradiographs after TIC separation of phos- 
pholipids. Results from three experiments (+ SEM) are shown. (b) Eth- 
anol does not inhibit TNF-stimulated I'2'DAG production. U937 cells 
were serum-starved and labded as described in Fig. 4. Calls left untreated 
(open symbols) or preincubated with 1% ethanol (solid symbols) were stimu- 
lated with TNF (O, O), OAG (A, A), and PMA (I-q, m). Changes of 
labeled DAG were estimated by two-dimensional scanning of the autoradio- 
graphs after separation of the neutral lipids by TIC. Results from three 
experiments are shown (_+  SEM). 
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Figure 6.  TNF has no effect on total PA mass. U937 cells were left 
untreated (O) or preincubated with propanolol for 5 min (0). Cells were 
stimulated  with  100  ng/ml  TNF  for  indicated  times.  For  control, 
propanolol-pretreated cells were incubated with 100 nM PMA (11) or 100 
/~M OAG (A) for 20 min. Phospholipids were separated by TIC, and 
the content of PA was determined by chafing densitometry  as described 
in Materials and Methods. Results of four experiments (_+ SEM) are shown. 
of DAG production (Fig. 2 a) and PKC activation  (Fig. 8 
b). These data were confirmed by experiments where the cells 
were prelabeled with [3H]arachidonic acid and liberation of 
free arachidonic acid was observed 15 min after TNF treat- 
ment (own unpublished observation), which is in accordance 
with the time course of PLA2 activation by TNF described 
for human synovial cells (22) and human neutrophils  (26). 
The delayed time course of PLA2 activation strongly argues 
against a role of PLA2 in mediating TNF activation of PKC. 
The  formation o.[ I'2'DAG Is a TNF Receptor-dependent  Event. 
We  next wanted to  examine whether the production of 
levels of PA probably  by inhibition of a constitutive  PA-  ~  80 
2  phosphohydrolase activity, a phenomenon that has already 
been observed with t-lyso-3-phosphatidylcholine,  1[114C]  -  - 
palmitoyl-labeled cells (Fig. 4 a). Again, TNF treatment did  o  6o  Q_ 
not induce PA accumulation. Thus, several  independent lines  & 
of evidence support the conclusion that TNF-induced DAG  ~  40 
formation does not result from operation of a PLD followed 
by PA degradation.  L~  20 
PLA2 Is Not Required  for TNF Activation of PKC.  Since 
the cleavage products of PLAz, free arachidonic acid, and 
o 
lyso-PC are potential activators of PKC (64-66), it was finally  ~  0 
necessary to examine whether TNF might stimulate  PKC 
via activation of PLAz. To this, PLA2 activity was monitored 
by TLC analysis of [14C]-labeled lyso-PC  in [t4C]choline- 
prelabeled U937 cells. TNF treatment resulted in an "~70% 
increase in lyso-PC, indicating that TNF, indeed, stimulates 
PLAz (Fig. 7). However, maximal PLA2 activation occurred 
between 10 and 15 min, clearly preceded by the time course 
,r 
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Activation of PLA2 by TNE U937 cells were prdabeled with 
[methyl t4C]choline for 48 h, serum-starved for 3 h, and incubated with 
100 ng/ml TNF for indicated times. [l~C]-hbded phospholipids were ana- 
lyzed by TLC and the content of lyso-PC calcuhted as percent of untreated 
controls.  Data from four experiments (_+  SD) are shown. 
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Figure 8.  Monoclonal  anti-TNF  re- 
ceptor  antibody H938 inhibits both 
TNF-induced I'2'DAG  production  and 
PKC activation. (a) U937 cells  were  la- 
beled with [14C]oleic acid for 16 h, 
serum-starved for 4 h, and incubated 
with 250 #g/ml anti-TNF receptor  an- 
tibody H398 for 15 min at 37~  be- 
fore treatment  with 50 ng/ml TNF for 
60 s, [14C]-1'2'DAG  content was ana- 
lyzed  by TIC and autoradiography,  and 
the TNF-induced  release  in I'2'DAG  es- 
timated as percent  of untreated  controls. 
(b) U937 cells left untreated (I) or 
pretreated with 250 #g/ml H398 for 
30 min at 37~  (A) were stimulated 
with  100 ng/ml TNF for indicated 
times. PKC activity  was determined  by 
[3H]PBt2 binding to whole cells as de- 
scribed in Materials and Methods. Per- 
cent maximal binding was calculated 
based on the means of quadruplicate 
assays (•  SEM)  from  three  experiments. 
I'2'DAG can be linked to TNF/TNF receptor interactions. 
U937 cells express •4,100  _+ 870 TNF binding sites per cell 
(53). It has been suggested that the 60-kD chain of the TNF 
receptor is essential for TNF signal transfer reactions (21). 
A monoclonal anti-TNF receptor p60 antibody, H398, was 
used in our study that competes for TNF binding and can 
inhibit a number of cellular responses to TNF (21). As shown 
in Fig. 8 a, pretreatment with mAb H398 completely abol- 
ished the TNF-induced release  of I'2'DAG in cells labeled 
with [14C]arachidonic acid, demonstrating that activation of 
the PC-specific phospholipase is a TNF receptor-dependent 
event.  As  expected,  pretreatment  with  mAb  H398  also 
prevented TNF-induced activation of PKC (Fig. 8 b), indi- 
cating that the TNF receptor p60 chain is also indispensable 
for PKC activation. 
TNF-induced  DAG Production Is Required for PKC Activa- 
tion.  We finally investigated whether TNF-induced DAG 
production is responsible for the subsequent activation of PKC. 
TNF-mediated activation and translocation of PKC in U937 
cells has been demonstrated in a previous report (30). First, 
TNF doses required for either DAG production or PKC acti- 
vation were compared. PKC stimulation by TNF was mea- 
sured by [3H]PBt2 binding of whole U937 cells, which has 
been shown to reveal essentially identical results when com- 
pared to the analysis of PKC activation by histone III-S phos- 
phorylation assays (30,  and see Fig.  11). As shown in Fig. 
9, half-maximal PKC activation was observed at 1.0 ng/ml 
TNF, which corresponds well with the TNF doses required 
for DAG production (see Fig.  2  b).  In a second approach, 
we used a phospholipase inhibitor, BPB, an alkylating agent 
that can modify histidine residues (67) and that has been shown 
to inhibit,  e.g.,  Ca2+-independent,  PC-specific PLC (68). 
This agent was used to dissect the role of DAG production 
for PKC activation in TNF-treated cells.  As shown in Fig. 
10 a BPB at 100 #M completely blocked the TNF-induced 
DAG release.  Basal DAG concentrations were not affected. 
BPB also completely inhibited TNF-stimulated PKC activa- 
tion (Fig.  10 b) as monitored by histone III-S phosphoryla- 
tion. In contrast, BPB did not block direct PKC stimulation 
by PMA (Fig.  11), demonstrating that PKC itself is not sen- 
sitive to BPB.  It is therefore, concluded that the activation 
of a PC-specific phospholipase providing DAG represents an 
important functional link between TNF receptors and PKC. 
Discussion 
Although the pleiotropic cellular effects of TNF are well 
established, little is known about the precise sequence of mo- 
lecular events that link the interaction of TNF with its cell 
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Figure 9.  TNF dose-dependent  activation  of PKC. U937 cells  were  in- 
cubated with indicated  TNF concentrations  for 3 min at 37~  Activation 
of PKC was determined  by [3H]PBt2  binding to whole cells as described 
in Materials and Methods. Percent  maximal  binding was calculated  based 
on the means of quadruplicate assays (•  SEM) from three experiments. 
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Figure I0.  Inhibition of TNF-induced I'2'DAG production  and PKC activation by BPB. (a) U937 calls were prelabeled with [14C]arachidonic  acid 
for 16 h and treated in the absence (11) or presence of 100/~M BPB (nil) with 100 ng/ml TNF for indicated times. [14C]l'2'DAG content was evaluated 
as described in the legend to Fig. 2 a. Results from three experiments (+SD) are shown.  (b) U937 cells were treated in the absence (A) or presence 
of 100/zM  BPB (V) with 100 ng/ml TNF for indicated times. PKC activity was determined by [3H]PBt2 binding. PKC activity is given as percent 
of maximal binding calculated from  the means  of quadruplicate  assays (+  SEM) from  three experiments. 
surface receptors to the transcriptional apparatus of the nu- 
cleus. Several lines of evidence suggest that protein phosphory- 
lation may play an important role: first, protein kinase inhib- 
itors could block TNF-mediated  gene induction  (27),  and 
second, TNF treatment results in rapid phosphorylation of 
small stress or heat shock proteins (33, 35),  of the receptor 
for  epidermal growth  factor (37),  and  of a  number  of 
unidentified cytosolic proteins in the range of 26-45 kD (32, 
38). Some of these phosphorylation events may be mediated 
by PKC, a major kinase system involved in many hormone 
signal transduction pathways (see reference 69 for review). 
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Figure lt.  BPB does not inhibit PMA-induced PKC activation.  U937 
cells were incubated with 100 #M BPB for 45 min or left untreated. Cells 
were then stimulated with 20 ng/ml PMA for 2 min or with 100 ng/ml 
TNF for 3 min. Cells were homogenized, and membrane-associated PKC 
activity was determined by histone III-S phosphorylation  assays.  Results 
of three experiments (+_  SEM) are shown. 
Interestingly, the kinetics of TNF-induced  PKC transloca- 
tion were found to differ  between various cell lines, suggesting 
a tissue-specific role for PKC in TNF signaling (30). In this 
report, we have addressed the molecular mechanisms that 
mediate TNF activation of PKC. Apparently, TNF does not 
induce a raise of intracellular Ca  2  + levels through IP3 turn- 
over leading to the release of Ca  2+ from internal stores. On 
the other hand, stimulation  of TNF receptors can trigger 
the activation of PLA2 (22-26), leading to the formation of 
arachidonic acid and lysophosphatidates. Both metabolites are 
potential activators of PKC (64-66).  However, the time course 
of TNF-induced  PLA2 activation was significantly delayed 
when compared to that of PKC activation (Fig.  12). Thus, 
PLA2 action does not seem to be required for TNF activa- 
tion of PKC. 
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Figure 12.  Sequential activation of PC-specific  phospholipase, PKC, and 
PLA2 by TNF in U937 cells. TNF-induced production of [t4C]I'2'DAG 
(0) was measured in [*4C]arachidonic acid-prelabeled cells as described 
in the legend to Fig. 2. PKC-activity (O -  -  -  O) was determined by 
[3H]PBt2 binding assays,  and  activation  of PLAz (')  was  assessed by 
measuring the liberation of [14C]lyso-PC from [14C]choline-prelabeled  cells 
(see Fig. 7). 
984  Tumor Necrosis Factor Stimulates l'2'Diacylglycerol  Production In the present report, we now show that TNF stimulates 
the rapid production of I'2'DAG, a "classical" activator of 
PKC.  The time course of DAG liberation precedes TNF- 
induced PKC activation (Fig. 12), suggesting that this com- 
ponent may mediate TNF stimulation of PKC. This assump- 
tion is further supported by the observation that both DAG 
production and PKC stimulation are initiated at similar TNF 
concentrations. Interestingly, DAG is liberated independent 
from PIP2 cleavage, but rather results from phosphatidylcho- 
line breakdown.  PC  as  source for DAG  production was 
identified by selective isotopic labeling of membrane phos- 
pholipids in U937 cells. Of note, increments of measurable 
DAG production depended on the radioactive precursor used 
for labeling the cellular phospholipids. Best results were ob- 
tained by short-term incubation of U937 cells with t-lyso-3- 
phosphatidylcholine,  1-[114C]palmitoyl,  which  revealed  a 
357% increase of DAG levels over untreated control. With 
this radioactive  precursor a highly efficient labeling of the 
PC pool was achieved, that is, 72% of the label was incorpo- 
rated  in  PC  compared  with  32.5%,  when  cells  were 
equilibrated with [14C]arachidonic acid label (Table 1). 
The strong influence of the isotopic precursor used for 
metabolic labeling on the amount of detectable DAG produc- 
tion merits consideration. It seems as if lysophosphatidate- 
acyhransferase converting the radioactive precursor lyso-PC 
to the PC substrate is localized  in close proximity to the 
TNF-responsive  PC  pool  within  U937  cell  membranes. 
Indeed, differential  compartmentation of labeled phospha- 
tidylcholine pools has been documented according to the ra- 
dioactive precursor used (70). In addition, hormone-responsive 
and -mlresponsive phospholipid pools have been described 
in pancreatic islets  (71). Thus,  our observation,  that use 
as  radiolabeled  precursors  of either  l-lyso-3-phosphatidyl 
[methyl ~4C]choline  or L-lyso-3-phosphatidylcholine, 1-[1~4C]  - 
palmitoyl revealed most pronounced PC decrease and incre- 
ments of both pchol and DAG, may be explained by the exis- 
tence of a select PC pool readily accessible and sensitive to 
TNF receptor-activated PLC. 
In the absence of IP3 turnover, DAG can be produced ei- 
ther directly by PLC or indirectly by PLD in combination 
with PA-phosphohydrolase.  As demonstrated in this report, 
several observations argue against an involvement of PLD in 
TNF-stimulated DAG production. First, in TNF-treated cells, 
the levels of PLD's primary reaction products, PA and cho- 
line, remained unchanged independent of the radioactive pre- 
cursor used.  Second, in the presence  of the PA-phospho- 
hydrolase inhibitor propanolol, TNF-induced DAG-production 
was unimpeded. Since propranolol prevents dephosphoryla- 
tion of PA (55, 58), an inhibition of DAG production, would 
have been expected if PLD and PA-phosphohydrolase were 
involved in TNF-induced DAG generation. Finally, in the 
presence of ethanol, which substitutes for H20 in the trans- 
phosphatidylation reaction catalyzed by PLD (57,  59, 60), 
TNF-induced formation of PEt was not detectable. Since PA 
metabolization to PEt in the presence  of ethanol prevents 
production of DAG (57),  an inhibition of TNF-stimulated 
DAG formation would be expected, if PA was the source for 
DAG.  Inhibition of TNF-induced DAG production, how- 
ever, was not observed after treatment of cells with ethanol. 
In concert, these findings indicate that PLD is not activated 
by TNF receptors within the time frame investigated. Rather, 
the time courses of PC degradation and production of both 
DAG and pchol strongly suggest the operation of a PC-PLC. 
Moreover,  the maximal amounts of pchol produced were 
equivalent to the amount of PC hydrolyzed, supporting the 
conclusion that TNF activates a PLC that directly hydrolyzes 
PC to pchol and DAG. 
DAG, in turn, appears to be the main mediator of TNF 
activation of PKC. The phospholipase inhibitor BPB did not 
only block DAG formation, but also TNF-induced PKC ac- 
tivation. It should be noted that BPB displays a broad range 
of inhibitory action, which is not restricted to phospholi- 
pases. However, since BPB did not inhibit PKC directly (Fig. 
8), our observations suggest that BPB inhibits TNF stimu- 
lation of PKC by blocking DAG generation. 
Both DAG release and PKC activation could be completely 
blocked by a mAb, H398, specific  for the 60-kD TNF receptor 
(21). Thus, the TNF receptor p60 appears to be an essential 
mediator of TNF-induced activation of both PC-PLC and 
PKC, which may account for (at least in part) the inhibitory 
action of mAb H398 on diverse TNF responses such as growth 
inhibition, HLA, or IL-2 receptor gene expression (21). Re- 
cent evidence indicates that many growth factors like epidermal 
growth factor,  platelet-derived growth factor,  insulin-like 
growth factor 1 induce by PC hydrolysis DAG production 
for prolonged periods of time and, thus, cause sustained acti- 
vation of PKC (72-75).  In contrast to these long-term effects, 
TNF mediates rapid and transient DAG generation as demon- 
strated in this study, resulting in rapid and transient PKC 
activation. Of note, TNF-induced DAG production from PC 
was also observed with other cell types, including the cervix 
carcinoma cell line HeLa and the leukemic promyelocytic cell 
line HL-60 (our unpublished observation), indicating that 
TNF-triggered hydrolysis is not restricted to U937 cells. The 
mechanism. The mechanism of Ca2+-independent short- 
term DAG production by TNF via PC-PLC activation is 
reminiscent of the mechanisms recently described for II:1 (76), 
IL-3 (77), CSF-1 (78), and IFN-o~ (79), indicating a possible 
common role for PC-PLC and PKC activation in the sig- 
naling pathways of these cytokines that may differ from that 
of other hormones. 
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